An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials
David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sarah P. Blagden(Churchill Hospital), Michael Flynn(Henry Ford Health System), Séan M. O’Cathail(Imperial College London), Michael J. Seckl(Charing Cross Hospital), Chara Stavraka(King's College London), David Olmos(Spanish National Cancer Research Centre), Martin Förster, Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Samantha Turnbull(University College London)
Cited by 33
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|JAMA Oncology|2019|582
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2023|317